IBA SA – Update following capital increase dated 03 December 2019

Written by Customer Service on . Posted in Public Companies.

IBA – DATA CONCERNING TRANSPARENCY
Heading II of the law of May 2, 2007 and the Royal Decree of February 14, 2008Louvain-la-Neuve, Belgium, December 03, 2019 – IBA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer, communicates today the basic and additional data as per Article 15 §1 al.1 of the Transparency Law, following its capital increase (further to exercises of stock options) dated December 03, 2019.Communication of the basic data as per Article 15 §1 al.1 of the LawTotal capital: EUR 42 294 182,30 Total number of securities conferring the voting right: 30 133 920Total number of voting rights (= the denominator): 30 133 920Total number of securities conferring the voting right, by category: N/ATotal number of voting rights, by category: N/ACommunication of the additional data as per Article 15 §1 al.2 of the LawTotal number of convertible bonds conferring the voting right: 0Total number of rights, materialized or not by certificates, giving the
right to subscribe to newly issued securities conferring the voting right
(e.g. warrants): 187 108Total number of voting rights which would result from the exercise of
these conversion or subscription rights: 187 108Total number of shares without voting right: 0Statutory thresholds as per Article 18 of the LawThe applicable thresholds as follows: three percent, five percent, ten percent, fifteen percent and so on by brackets of five percentAbout IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.comFor further information, please contact:IBA
Elodie Jaumain
Paralegal
+32 10 203 180
elodie.jaumain@iba-group.comAttachment20191203EvolutionofthebasicdataEN

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.